Lexicon Pharmaceuticals (LXRX) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.37 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.38. The company posted revenue of $20.09 million in the period, compared to analysts expectations of $14.77 million. The company’s revenue was up 5186.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.
Many Wall Street Analysts have commented on Lexicon Pharmaceuticals. Citigroup Initiated Lexicon Pharmaceuticals on Aug 2, 2016 to “Buy”, Price Target of the shares are set at $21.
Lexicon Pharmaceuticals closed down -0.73 points or -4.37% at $15.99 with 8,41,619 shares getting traded on Tusday. Post opening the session at $16.83, the shares hit an intraday low of $15.89 and an intraday high of $16.89 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jun 8, 2016, James F Tessmer (VP, Finance & Accounting) sold 1,500 shares at $15.00 per share price.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.